Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Tables)

v3.21.2
SEGMENT REPORTING (Tables)
6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

Information concerning the operations of the Company’s reportable segments is as follows:

 

   

BioSig

Technologies, Inc.

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Revenue:

                               

Product sales

  $ 199     $ -     $ -     $ 199  

Service

    8       -       -       8  

Total Revenue

    207       -       -       207  
                                 

Cost of goods sold

    62       -       -       62  
                                 

Gross profit

    145       -       -       145  
                                 

Operating expenses:

                               

Research and development

    1,455       212       -       1,667  

General and administrative

    5,523       953       4       6,480  

Depreciation and amortization

    48       1       -       49  

Total operating expenses

    7,026       1,166       4       8,196  
                                 

Loss from operations

    (6,881

)

    (1,166

)

    (4

)

    (8,051

)

                                 

Other income:

                               

Interest income and other income, net

    -       -       -       -  
                                 

Net loss

  $ (6,881

)

  $ (1,166

)

  $ (4

)

  $ (8,051

)

 

   

BioSig

Technologies, Inc

   

ViralClear

Pharmaceuticals, Inc.

   

Total

 

Operating expenses:

                       

Research and development

  $ 1,087     $ 4,631     $ 5,718  

General and administrative

    8,128       8,480       16,608  

Depreciation and amortization

    22       -       22  

Total operating expenses

    9,237       13,111       22,348  
                         

Loss from Operations

    (9,237

)

    (13,111

)

    (22,348

)

                         

Other income:

                       

Interest income and other income, net

    2       -       2  
                         

Net loss

  $ (9,235

)

  $ (13,111

)

  $ (22,346

)

 

   

BioSig

Technologies, Inc.

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Revenue:

                               

Product sales

  $ 314     $ -     $ -     $ 314  

Service

    11       -       -       11  

Total Revenue

    325       -       -       325  
                                 

Cost of goods sold

    161       -       -       161  
                                 

Gross profit

    164       -       -       164  
                                 

Operating expenses:

                               

Research and development

    2,731       202       -       2,933  

General and administrative

    11,980       1,767       4       13,751  

Depreciation and amortization

    89       2       -       91  

Total operating expenses

    14,800       1,971       4       16,775  
                                 

Loss from operations

    (14,636

)

    (1,971

)

    (4

)

    (16,611

)

                                 

Other income:

                               

Interest income and other income, net

    1       -       -       1  
                                 

Net loss

  $ (14,635

)

  $ (1,971

)

  $ (4

)

  $ (16,610

)

 

   

BioSig

Technologies, Inc

   

ViralClear

Pharmaceuticals, Inc.

   

Total

 

Operating expenses:

                       

Research and development

  $ 2,414     $ 8,231     $ 10,645  

General and administrative

    11,949       12,515       24,464  

Depreciation and amortization

    43       -       43  

Total operating expenses

    14,406       20,746       35,152  
                         

Loss from Operations

    (14,406

)

    (20,746

)

    (35,152

)

                         

Other income:

                       

Interest and other income, net

    28       14       42  
                         

Net loss

  $ (14,378

)

  $ (20,732

)

  $ (35,110

)

 

   

BioSig

Technologies, Inc.

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Cash

  $ 12,445     $ 3,059     $ -     $ 15,504  

Accounts receivable

    199       -       -       199  

Inventory

    731       -       -       731  

Other current assets

    513       2       -       515  

Total operating assets

    13,888       3,061       -       16,949  
                                 

Property and equipment, net

    382       6       -       388  

Right-to-use assets, net 

    252       -       -       252  

Other assets

    438       -       -       438  
                                 

Total assets

  $ 14,960     $ 3,067     $ -     $ 18,027